Mesoblast Limited

The Business

Mesoblast's approved product, Ryoncil, treats steroid-refractory acute graft-versus-host disease in children, a rare but severe complication of bone marrow transplant. It is the only approved cell therapy for the condition, giving Mesoblast effective pricing power and no direct substitute. The company is now trying to extend the same cell platform into adult graft-versus-host disease, chronic low back pain, and heart failure, each requiring its own separate clinical trial and FDA approval. Manufacturing is outsourced to Lonza, keeping the business asset-light but concentrating supply risk with a single partner.

Recent Performance

Revenue jumped from $17.2 million in FY25 to $120.3 million in FY26, the first full commercial year of Ryoncil. That growth looks extraordinary in percentage terms, but it is flattered by an almost negligible prior-year base, since FY25 itself was a pre-launch year. The more telling number is the underlying run rate: fourth-quarter sales annualised to roughly $144 million, which is what has driven the stock's substantial re-rating over the past year.

Outlook

We expect revenue growth to moderate over the next two years as the paediatric franchise matures off its new, much larger base, before a step change higher later in the forecast period if an adult graft-versus-host disease launch begins contributing as assumed. Earnings before interest, tax, depreciation and amortisation (EBITDA) is expected to turn positive within the next year or two and expand meaningfully as trial costs roll off. Net losses are expected to persist through the medium term but narrow considerably from the $57.5 million recorded in FY26.

Key Risks

The single largest swing factor for this stock is the outcome of the Phase 3 trial in chronic low back pain. Pain trials of this type have historically succeeded only about a third of the time, and a failed readout would eliminate the blockbuster narrative currently underpinning market enthusiasm, likely forcing an accounting impairment against the pipeline asset on the balance sheet. A second, related risk sits in the adult graft-versus-host disease program, where an existing approved competitor treatment is already on the market; a negative trial outcome here would remove the growth pillar currently expected to drive the next leg of revenue expansion. A third, lower-probability risk is that the existing paediatric franchise is already reaching saturation, having achieved high penetration of a very small eligible patient population within its first year, which caps how much organic growth this segment alone can deliver.

What to Watch

The thesis-defining event is the Phase 3 primary endpoint readout for chronic low back pain, expected mid-CY2027. This single binary outcome will do more to resolve the current valuation debate than any other event on the calendar.

• Mid-CY2027 CLBP Phase 3 primary endpoint readout — binary outcome that will materially reprice the stock in either direction.
• Q4 CY2027 Adult aGvHD interim trial data — secondary catalyst for the label-extension growth pillar.
• Oct-Dec 2026 Quarterly Ryoncil revenue prints — will confirm whether the paediatric franchise sustains its current run rate.

Company Description

Mesoblast is a cell therapy company built on a single technology platform: donor-derived mesenchymal stromal cells engineered to dampen inflammation and immune response. Its lead product, Ryoncil, is approved for steroid-refractory acute graft-versus-host disease in children, currently the sole source of commercial revenue. Beyond that, the pipeline includes an adult version of the same graft-versus-host disease indication, a Phase 3 program in chronic low back pain, and an earlier-stage heart failure program. Manufacturing runs through a partnership with Lonza rather than in-house facilities, keeping capital intensity low but concentrating operational risk in one external relationship.

Where the Growth Is

The clearest near-term growth lever is the adult graft-versus-host disease label extension, expected to launch later in the forecast period and ramp over several years toward a peak revenue opportunity broadly comparable in size to the existing paediatric franchise. This indication carries a meaningful probability of approval based on the underlying clinical pathway, and it is also the growth driver most exposed to competition, given an existing approved treatment for adult patients already on the market.

Competitive Position

Mesoblast's core advantage is regulatory: it is the only company globally with an FDA-approved mesenchymal stromal cell therapy, a position competitors are years away from replicating given the length of the clinical and regulatory pathway. That position is reinforced by a patent estate of more than 1,100 filings extending to 2044, and by manufacturing know-how built over a decade of allogeneic (donor-derived, off-the-shelf) cell production, which is a materially different and more scalable model than the patient-specific manufacturing used by rival cell therapies. We regard this competitive position as stable rather than widening, since it protects a narrow, currently small commercial franchise rather than a broad addressable market.

Management & Capital Discipline

Management has directed capital almost entirely toward pipeline development, accumulating $1.07 billion in losses over the company's history in pursuit of the first FDA approval for this cell therapy class, which it ultimately achieved. That approval, and a stronger-than-expected initial commercial launch, are verifiable wins. The honest caveat is that management's operational and clinical execution claims have proven credible, while its forward-looking projections for pipeline market size and peak revenue have consistently run ahead of what the underlying trial data supports.

Financial Position

The balance sheet carries $103 million in cash plus access to a $125 million credit facility, providing an estimated five or more years of runway at current spending levels. Half-year operating cash burn has narrowed to $13.4 million from $30.4 million in the prior half, evidence that the cost base is adjusting as trial spending declines. There is no near-term liquidity risk, though a portion of the funding facility is provided by a related party, which is a governance point worth monitoring rather than an immediate financial concern.